Status:
ACTIVE_NOT_RECRUITING
Personalizing Osteoporosis Care: Clinical & Genetic Risk Factors for AFFs
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Atypical Femur Fracture
Eligibility:
FEMALE
18+ years
Brief Summary
The overall objective of this project is to identify clinical and genetic risk factors for Atypical Femur Fractures (AFFs) in Anti-resorptive therapy (ART) users by conducting a case control study of ...
Detailed Description
Antiresorptive therapy (ART) drugs are effective osteoporosis treatment and help decrease osteoporosis-related fractures. However, their long-term use has been associated with rare but serious atypica...
Eligibility Criteria
Inclusion
- Cases: Have experienced a confirmed, documented Atypical femur fracture
- Controls: currently on anti-resorptive therapy, matches AFF case by age, race and length of ART use
Exclusion
- \-
Key Trial Info
Start Date :
June 25 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04110795
Start Date
June 25 2018
End Date
December 31 2027
Last Update
June 1 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Adachi Medical Centre
Hamilton, Ontario, Canada, L8N 1Y2
2
Bone Research & Education Centre
Oakville, Ontario, Canada, L6M 1M1
3
University Health Network, TGH
Toronto, Ontario, Canada, M5G 2C4